Xenografted Human Tumors in Preclinical Drug Design
More than 100 human tumors were transplanted into artificially immunosuppressed CBA mice with an overall success rate of 24% (16% colorectal carcinoma, 22% renal cell carcinoma, 12% NHL etc.). These tumor panels were used to evaluate the correspondence between the results obtained with known drugs in clinical practice and in xenograft models. Using the value of “growth delay” for drug ranking the response was considered as positive when over 0.5. Although it is still unknown whether the panel is representative of the tumor population at large, the good agreement between sensitivity of xenografted tumors and clinical experience indicated the usefulness of the model. Several newly developed structures have been tested and some of them produced considerable growth inhibition alone or in combination (e.g. bifunctional nitrosourea, EUdR + 5-FU for colorectal carcinoma, MSHfragment nitrosourea for melanoma, DAG for lymphoma etc.).